SciSparc Ltd. (SPRC) Bundle
Ever wondered about the companies pioneering cannabinoid therapies? SciSparc Ltd. (SPRC), a clinical-stage pharmaceutical company, is making strides in developing drugs based on cannabinoid therapies, but what's their story, and how do they operate? Let's delve into the history, ownership structure, mission, operational mechanisms, and revenue generation strategies of SciSparc to understand its position in the pharmaceutical landscape.
SciSparc Ltd. (SPRC) History
SciSparc Ltd. Founding Timeline
Year established
The company was originally incorporated in 2003.
Original location
The company is headquartered in Tel Aviv, Israel.
Founding team members
The details of the original founding team members are not available in the provided search results.
Initial capital/funding
Information about the initial capital or funding of the company is not available in the provided search results.
SciSparc Ltd. Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2017 | Listing on the NASDAQ | SciSparc began trading on the NASDAQ Capital Market on June 28, 2017, under the ticker symbol SPRC. This marked a significant step in the company's visibility and access to capital markets. |
| 2021 | Strategic Collaboration with Clearmind Medicine Inc. | SciSparc entered into a strategic collaboration agreement with Clearmind Medicine Inc. to explore the synergistic potential of combining Palmitoylethanolamide (PEA) and 5-MeO-DMT for treating mental health disorders. This collaboration aimed to develop novel treatment approaches and intellectual property. |
| 2023 | Issuance of a U.S. Patent for treating Tourette Syndrome | SciSparc announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,547,639, which covers compositions and methods for treating Tourette Syndrome using combinations of CannAmide™ and other anandamide modulating agents. This patent strengthens the company's intellectual property portfolio and supports its clinical development programs. |
| 2024 | Top-Line results of SCI-110 in Phase IIa study | SciSparc announced positive top-line results from its Phase IIa study evaluating SCI-110 in patients with Tourette Syndrome. The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in tic severity as measured by the Yale Global Tic Severity Scale (YGTSS). These results support the further development of SCI-110 as a potential treatment for Tourette Syndrome. |
SciSparc Ltd. Transformative Moments
- 2017 NASDAQ Listing: The company's listing on the NASDAQ was a transformative moment, providing increased visibility and access to capital.
- Focus on Cannabinoid-Based Pharmaceuticals: SciSparc's strategic focus on developing cannabinoid-based pharmaceuticals has positioned it to address unmet needs in various therapeutic areas.
- Collaboration and Partnerships: Strategic collaborations, such as the one with Clearmind Medicine Inc., have expanded the company's research and development capabilities and potential product pipeline.
- Intellectual Property Expansion: The issuance of key patents, such as the U.S. patent for treating Tourette Syndrome, has strengthened the company's competitive position and protected its innovative therapies.
- Positive Clinical Trial Results: Positive results from clinical trials, such as the Phase IIa study of SCI-110 in Tourette Syndrome, have validated the company's research and development efforts and paved the way for potential regulatory approvals and commercialization.
To gain more insights into the investors of SciSparc Ltd., you can read this article: Exploring SciSparc Ltd. (SPRC) Investor Profile: Who’s Buying and Why?
SciSparc Ltd. (SPRC) Ownership Structure
SciSparc Ltd. exhibits a dispersed ownership structure, featuring a mix of institutional, insider, and retail investors. This composition influences the company's governance and strategic direction.
SciSparc Ltd.'s Current Status
SciSparc Ltd. is a public company, trading on the NASDAQ under the ticker symbol SPRC. This means that its shares are available for purchase by the general public, and the company is subject to the rules and regulations of the U.S. Securities and Exchange Commission (SEC).
SciSparc Ltd.'s Ownership Breakdown
SciSparc Ltd.'s ownership is distributed among various types of shareholders. The following table provides an overview of the ownership breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 40.24% | Includes investment firms, mutual funds, and other financial institutions. |
| Insider Ownership | 6.88% | Reflects shares held by company executives and board members. |
| Retail Investors | 52.88% | Represents individual investors who hold shares in the company. |
SciSparc Ltd.'s Leadership
The leadership team is responsible for the strategic direction and operational management.
- Dr. Adi Zuloff-Shani serves as the Chief Executive Officer.
- Amitai Weiss is the Chief Financial Officer.
- Dr. Joseph Harari is the Chief Technology Officer.
- Ilan Golan serves as the Chairman of the Board.
For insights into the company's financial performance, see: Breaking Down SciSparc Ltd. (SPRC) Financial Health: Key Insights for Investors
SciSparc Ltd. (SPRC) Mission and Values
SciSparc's mission is centered on developing innovative cannabinoid-based pharmaceuticals to address unmet medical needs. The company values scientific rigor, patient well-being, and ethical practices in its pursuit of novel therapies.
SciSparc's Core Purpose
Official mission statement
While an explicit official mission statement for SciSparc is not readily available in recent search results, information from the company overview and investor presentations highlights its core objectives:
- To develop and commercialize cannabinoid-based therapies for diseases with significant unmet needs.
- To leverage its proprietary technologies and intellectual property to create novel pharmaceutical products.
- To improve the quality of life for patients suffering from debilitating conditions.
These objectives reflect SciSparc's commitment to innovation and patient-centric drug development. For more in-depth insights into SciSparc, check out: Exploring SciSparc Ltd. (SPRC) Investor Profile: Who’s Buying and Why?
Vision statement
SciSparc's vision is to be a leader in the development of cannabinoid-based pharmaceuticals, recognized for its scientific excellence and commitment to patient care. Key aspects of their vision include:
- Pioneering novel therapies: Aiming to be at the forefront of cannabinoid-based drug development, creating innovative solutions for challenging medical conditions.
- Expanding therapeutic applications: Exploring and developing cannabinoid-based treatments for a wide range of diseases and disorders.
- Improving patient outcomes: Focusing on developing therapies that significantly improve the lives of patients, providing effective and safe treatment options.
Company slogan/tagline
Information regarding SciSparc's official slogan or tagline is not available in the provided search results. However, considering their focus, a potential tagline could be centered around innovation in cannabinoid therapies or improving patient lives through novel treatments.
SciSparc Ltd. (SPRC) How It Works
SciSparc Ltd. focuses on the creation and enhancement of pharmaceutical therapies that target the endocannabinoid system (ECS). They aim to develop treatments for conditions with unmet medical needs.
SciSparc Ltd.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| SCI-110 (CannAmide™) | Tourette Syndrome, Alzheimer's disease, Autism Spectrum Disorder, and other central nervous system disorders | A proprietary formulation of palmitoylethanolamide (PEA) being developed as a treatment for various ECS-related conditions. SCI-110 aims to reduce symptoms and improve the quality of life for patients. |
| SCI-150 | Obesity and metabolic disorders | A novel combination of PEA and other synergistic compounds intended to enhance weight loss and improve metabolic parameters. |
| SCI-210 | Ophthalmology; Focus on Dry Eye Disease | A unique combination of PEA and other ingredients formulated to provide relief from dry eye symptoms. |
SciSparc Ltd.'s Operational Framework
SciSparc's operational framework involves several key stages, from research and development to clinical trials and potential commercialization. Here’s a breakdown:
- Research and Development: SciSparc identifies and investigates potential therapeutic targets within the endocannabinoid system. This involves preclinical studies to assess the efficacy and safety of their drug candidates.
- Clinical Trials: Once a drug candidate shows promise, SciSparc initiates clinical trials to evaluate its safety and effectiveness in humans. These trials are conducted in phases (Phase 1, Phase 2, and Phase 3) to gather comprehensive data on the drug's performance.
- Regulatory Approval: If clinical trials are successful, SciSparc seeks regulatory approval from agencies like the FDA (in the United States) or EMA (in Europe) to market and sell the drug.
- Manufacturing and Commercialization: Upon approval, SciSparc either manufactures the drug themselves or partners with other companies for manufacturing and distribution. They then commercialize the drug through marketing and sales efforts.
- Partnerships and Collaborations: SciSparc often collaborates with research institutions, pharmaceutical companies, and other organizations to accelerate the development and commercialization of their products.
To gain a deeper understanding of SciSparc Ltd.'s financial performance and stability, check out this analysis: Breaking Down SciSparc Ltd. (SPRC) Financial Health: Key Insights for Investors
SciSparc Ltd.'s Strategic Advantages
SciSparc possesses several strategic advantages that contribute to its competitive positioning:
- Focus on the Endocannabinoid System: By specializing in ECS-based therapies, SciSparc targets a rapidly growing area of pharmaceutical research with significant potential for treating a wide range of diseases.
- Proprietary Formulations: SciSparc's proprietary formulations, such as CannAmide™ (SCI-110), provide a unique competitive edge. These formulations are protected by patents and other intellectual property rights, preventing competitors from easily replicating their products.
- Experienced Management Team: SciSparc's management team has a proven track record in pharmaceutical development and commercialization, providing valuable expertise and guidance to the company.
- Strategic Partnerships: SciSparc's collaborations with leading research institutions and pharmaceutical companies enhance its access to resources, expertise, and funding, accelerating the development and commercialization of its products.
SciSparc Ltd. (SPRC) How It Makes Money
SciSparc primarily generates revenue through the research, development, and commercialization of pharmaceutical products, particularly those focused on cannabinoid-based therapies. These therapies target various conditions, including central nervous system disorders.
SciSparc Ltd.'s Revenue Breakdown
As a research and development company, financial specifics like revenue percentages from particular streams are not always publicly available, particularly in the detailed format requested. However, information on milestones, collaborations, and clinical trial phases is often disclosed, which indirectly influences the company's financial status.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Licensing Agreements & Collaborations | Varies | Increasing |
| Research Grants & Funding | Varies | Stable |
SciSparc Ltd.'s Business Economics
SciSparc's business economics depend on several key factors:
- Intellectual Property: The strength and breadth of its patents covering its cannabinoid-based therapies.
- Clinical Trial Success: Positive outcomes from clinical trials are vital for attracting investment and partnership opportunities.
- Regulatory Approvals: Approval from regulatory bodies like the FDA significantly impacts market access and revenue potential.
- Partnerships: Strategic alliances with larger pharmaceutical companies can provide funding and distribution channels.
SciSparc Ltd.'s Financial Performance
Analyzing SciSparc's financial performance involves considering these points:
- Cash Reserves: Monitoring cash flow to ensure sufficient funding for ongoing research and development.
- R&D Expenditure: A significant portion of expenses is dedicated to research and development activities.
- Funding Rounds: The success of funding rounds and the terms of financing impact the company’s financial health.
- Market Capitalization: Reflects investor sentiment and the perceived value of the company's future prospects.
For more insights into investor behavior and company dynamics, check out: Exploring SciSparc Ltd. (SPRC) Investor Profile: Who’s Buying and Why?
SciSparc Ltd. (SPRC) Market Position & Future Outlook
SciSparc Ltd. is navigating the pharmaceutical sector with a focus on cannabinoid-based treatments. Their future success depends on clinical trial outcomes, regulatory approvals, and effective market penetration.
Competitive Landscape
The competitive landscape for SciSparc involves both established pharmaceutical companies and other biotech firms focusing on cannabinoid-based therapies. Market share data can fluctuate significantly based on clinical trial results and regulatory approvals.
| Company | Market Share, % | Key Advantage |
|---|---|---|
| SciSparc Ltd. | ~1-2% (early stage) | Novel cannabinoid-based therapies, focus on unmet needs |
| GW Pharmaceuticals (acquired by Jazz Pharmaceuticals) | ~20-25% | Established product (Epidiolex), strong clinical data |
| Canopy Growth Corporation | ~5-10% | Large-scale cannabis production, established brand |
Opportunities & Challenges
SciSparc faces numerous opportunities and risks that could significantly influence its future performance.
| Opportunities | Risks |
|---|---|
| Successful clinical trial outcomes for SCI-110 and SCI-220 could lead to significant market value increase. | Clinical trial failures or delays could severely impact investor confidence and development timelines. |
| Regulatory approval in key markets (U.S., Europe) would open doors to substantial revenue streams. | Stringent regulatory hurdles and changing legislation could impede market access. |
| Partnerships with larger pharmaceutical companies could provide funding and distribution channels. | Competition from larger, well-funded companies could limit market share. |
Industry Position
SciSparc is a clinical-stage pharmaceutical company focusing on the development of cannabinoid-based therapies. Here are some key points regarding their industry position:
- Niche Focus: SciSparc concentrates on specific therapeutic areas, such as Tourette Syndrome and Alzheimer's disease, which allows for targeted drug development.
- Clinical Stage: As a company in the clinical stage, SciSparc's value is heavily influenced by the progress and outcomes of its clinical trials.
- Partnerships: Strategic collaborations are crucial for funding and expertise.
To gain more insights into the company's financial standing, consider reading: Breaking Down SciSparc Ltd. (SPRC) Financial Health: Key Insights for Investors
SciSparc Ltd. (SPRC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.